BR112022018238A2 - Método de tratamento de um câncer em um sujeito - Google Patents

Método de tratamento de um câncer em um sujeito

Info

Publication number
BR112022018238A2
BR112022018238A2 BR112022018238A BR112022018238A BR112022018238A2 BR 112022018238 A2 BR112022018238 A2 BR 112022018238A2 BR 112022018238 A BR112022018238 A BR 112022018238A BR 112022018238 A BR112022018238 A BR 112022018238A BR 112022018238 A2 BR112022018238 A2 BR 112022018238A2
Authority
BR
Brazil
Prior art keywords
treatment
cancer
subject
thio
immunodependent
Prior art date
Application number
BR112022018238A
Other languages
English (en)
Portuguese (pt)
Inventor
Shay Jerry
Fu Yang-Xin
Mender Ilgen
Zhang Anli
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR112022018238A2 publication Critical patent/BR112022018238A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
BR112022018238A 2020-03-13 2021-03-12 Método de tratamento de um câncer em um sujeito BR112022018238A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062989041P 2020-03-13 2020-03-13
PCT/US2021/022090 WO2021183873A1 (en) 2020-03-13 2021-03-12 Sequential treatment of cancers using 6-thio-dg, checkpoint inhibitors and radiation therapy

Publications (1)

Publication Number Publication Date
BR112022018238A2 true BR112022018238A2 (pt) 2022-10-25

Family

ID=77671975

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018238A BR112022018238A2 (pt) 2020-03-13 2021-03-12 Método de tratamento de um câncer em um sujeito

Country Status (17)

Country Link
US (2) US12097213B2 (enExample)
EP (1) EP4117667B1 (enExample)
JP (1) JP7829491B2 (enExample)
KR (1) KR20220154134A (enExample)
CN (1) CN115397428A (enExample)
AU (2) AU2021233023B9 (enExample)
BR (1) BR112022018238A2 (enExample)
CA (1) CA3170930A1 (enExample)
DK (1) DK4117667T3 (enExample)
ES (1) ES3014683T3 (enExample)
FI (1) FI4117667T3 (enExample)
HU (1) HUE070513T2 (enExample)
IL (1) IL296403A (enExample)
MX (1) MX2022011331A (enExample)
PL (1) PL4117667T3 (enExample)
PT (1) PT4117667T (enExample)
WO (1) WO2021183873A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210023107A1 (en) 2018-03-22 2021-01-28 The Board Of Regents Of The University Of Texas System USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS
WO2025090539A1 (en) * 2023-10-22 2025-05-01 Regeneron Pharmaceuticals, Inc. Treatment of non-small cell lung cancer with 6-thio-dg and cemiplimab

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103180463B (zh) 2010-10-22 2014-12-31 霍夫曼-拉罗奇有限公司 亲硫性固相以及包含硫代羰基核苷酸的寡核苷酸的缀合物
KR20150143587A (ko) 2013-04-08 2015-12-23 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 텔로머라제 매개된 텔로미어를 변형시키기 위한 메르캅토푸린 리보뉴클레오시드 유사체
CA2991628C (en) * 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
US20180036331A1 (en) 2016-03-24 2018-02-08 The Board Of Regents Of The University Of Texas System Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds
EP3463370A4 (en) 2016-05-27 2020-04-08 The Board of Regents of The University of Texas System 6-THIO-2'-DEOXYGUANOSINE (6-THIO-DG) RESULTS IN TELOMERASE-DEPENDENT TELOMER DYS FUNCTION AND CELL DEATH IN THERAPY-RESISTANT CANCER CELL
CA3035262A1 (en) 2016-09-16 2018-03-22 Tina Christine Lavranos Antibody and checkpoint inhibitor combination therapy
CN117442719A (zh) * 2017-02-21 2024-01-26 瑞泽恩制药公司 用于治疗肺癌的抗pd-1抗体
KR20200020662A (ko) * 2017-04-03 2020-02-26 온콜로지, 인크. 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
US20210363243A1 (en) * 2018-02-01 2021-11-25 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody
US20210113602A1 (en) 2018-02-28 2021-04-22 The Board Of Regents Of The University Of Texas System USE OF 6-THIO-2'-DEOXYGUANOSINE (6-THIO-dG) TO TREAT MELANOMA
US20210023107A1 (en) 2018-03-22 2021-01-28 The Board Of Regents Of The University Of Texas System USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS

Also Published As

Publication number Publication date
US20210290652A1 (en) 2021-09-23
JP2023517671A (ja) 2023-04-26
CA3170930A1 (en) 2021-09-16
US20240424013A1 (en) 2024-12-26
FI4117667T3 (fi) 2025-02-10
HUE070513T2 (hu) 2025-06-28
JP7829491B2 (ja) 2026-03-13
PL4117667T3 (pl) 2025-04-07
EP4117667B1 (en) 2024-12-18
KR20220154134A (ko) 2022-11-21
AU2021233023B2 (en) 2026-04-16
EP4117667A4 (en) 2023-11-15
ES3014683T3 (en) 2025-04-24
AU2021233023B9 (en) 2026-05-07
PT4117667T (pt) 2025-02-06
MX2022011331A (es) 2022-10-27
CN115397428A (zh) 2022-11-25
EP4117667A1 (en) 2023-01-18
AU2021233023A1 (en) 2022-11-03
IL296403A (en) 2022-11-01
WO2021183873A1 (en) 2021-09-16
DK4117667T3 (da) 2025-02-10
AU2026206150A1 (en) 2026-08-06
US12097213B2 (en) 2024-09-24

Similar Documents

Publication Publication Date Title
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
MX2021007927A (es) Metodos para tratar trastornos usando inhibidores de csf1r.
MX2018013848A (es) Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer.
MX2022014180A (es) Metodos, terapias y usos para tratar cancer.
BR112019021822A2 (pt) Terapia de combinação
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
MX420412B (es) Plinabulina, composiciones que la comprenden y sus usos en el tratamiento de cáncer asociado con mutación del egfr.
MX2021012977A (es) Tratamiento del cáncer con tg02.
ZA201907225B (en) Treatment of her2 positive cancers
MX2023003034A (es) Metodos, terapias y usos para tratar el cancer.
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
BR112023018944A2 (pt) Composição de terapia gênica e tratamento de cardiomiopatia arritmogênica ventricular direita
BR112016023025A2 (pt) direcionamento de câncer de mama her2+ resistente a trastuzumab com uma nanopartícula de direcionamento de her3
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
JOP20200124A1 (ar) طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
CL2025001869A1 (es) Uso de diferentes compuestos inhibidores de quinasas para tratar cáncer.
PH12022551078A1 (en) Combination therapy to treat brain cancer
BRPI0511187A (pt) método para tratar cáncer em um indivìduo
BR112021021787A2 (pt) Terapias de combinação
CL2019000846A1 (es) Proteína terapéutica.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2022011331A (es) Tratamiento secuencial de canceres utilizando 6-tio-dg, inhibidores de puntos de control y radioterapia.
ATE506062T1 (de) Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11